Opinion on Pharmaceuticals and Healthcare in Germany

Published within

« | ... | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

AstraZeneca/Schwarz: contrasting ulcer fortunes

Company results released on 30 April by companies on either side of the branded versus generic fence show contrasting fortunes in the valuable market for ulcer drug omeprazole. While AstraZeneca's gastrointestinal franchise shrank by 3% compared with a year before, Schwarz's increased omeprazole manufacturing capacity is helping to drive growth.

Published By Datamonitor
02 May 2003
CommentWire
CommentWire

Plant vaccines: growing closer to commercial reality

Transgenic plant technologies could lead to a revolution in vaccine production and manufacture. Should plant-based vaccines prove effective in clinical trials, this will drive licensing activity between key vaccine players and companies with relevant intellectual property.

Published By Datamonitor
20 Aug 2003
CommentWire
CommentWire

UK pharmaceuticals: potential pricing safe haven

With healthcare reform and cost containment initiatives taking hold throughout Europe, the UK is becoming increasingly attractive to the branded pharmaceutical sector. Through price control deregulation the UK government could attract increased investment, but it must be careful to balance the interests of patients with those of the industry.<BR />

Published By Datamonitor
17 Sep 2003
CommentWire
CommentWire

Bayer: too little, too late?

Bayer's [BAY.F] company structure has been modernized, with its conglomerate model streamlined to allow its four major components the freedom to operate independently and undergo M&A. However, the Healthcare division's portfolio is such that it may have trouble even finding a potential merger partner.

Published By Datamonitor
01 Oct 2003
CommentWire
CommentWire

Merck KGaA: good news finally for Erbitux

Swiss regulators have recommended the approval of Merck KGaA's [MRK.F] Erbitux as a second-line therapy for colorectal cancer. The drug is set to be approved within 30 days and Switzerland will be the first market to approve the drug. Given Erbitux's past difficulties, it is welcome news, not only for Merck, but also for ImClone [IMCL] and BMS [BMY].

Published By Datamonitor
17 Nov 2003
CommentWire
CommentWire

Lilly ICOS: Cialis third to tango

Lilly ICOS' Cialis joins Bayer [BAY.F]/GSK's [GSK.L] Levitra and Pfizer's [PFZ.L] Viagra in the fight against erectile dysfunction after receiving FDA approval earlier this month. Although Cialis offers several advantages over rival products, Lilly ICOS will have to go head-to-head with the leading players. This makes the adoption of effective promotional campaigns vital for success.

Published By Datamonitor
27 Nov 2003
CommentWire
CommentWire

Bayer: in-licensing required to address decline

As Bayer [BAY.F] restructures, the management needs to take urgent steps to address declining pharmaceutical sales. Bayer would benefit from in-licensing drugs from other companies or creating joint-venture partnerships to address short-term revenue issues. In the long-term, the company should seek to bolster its biotechnology division with increased investment.

Published By Datamonitor
17 Dec 2003
CommentWire
CommentWire

Pfizer: Aromasin patent could dampen its potential

Clinical trial data has shown that post-menopausal women with breast cancer who were treated using Aromasin demonstrated a significantly reduced risk of recurrence and increased disease-free survival than those treated with tamoxifen. With Aromasin's patent up in 2006, Pfizer [PFE] should now concentrate on marketing this product as a second-line treatment.

Published By Datamonitor
22 Mar 2004
CommentWire
CommentWire

Sanofi/Aventis: the long awaited merger

Ever since the merger of Pfizer [PFE] and Pharmacia, there has been intense speculation as to which company would be the next merger candidate. This week Sanofi-Synthelabo [SAN.PA] and Aventis [AVE.L] finally agreed to a merger after months of rumors linking the two companies. The deal will leave rivals Pfizer and GSK {GSK.L] looking over their shoulders at a new third-ranked pharma.

Published By Datamonitor
27 Apr 2004
ResearchWire
ResearchWire

eHealth: Italy has the highest penetration of online CME in Europe

Published By Datamonitor
11 Jun 2004

« | ... | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | ... | » »|

No help is available.